Grifols, S.A. $GRFS is Brandes Investment Partners LP’s 5th Largest Position

Brandes Investment Partners LP increased its holdings in Grifols, S.A. (NASDAQ:GRFS) by 6.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 30,954,223 shares of the biotechnology company’s stock after purchasing an additional 1,838,727 shares during the period. Grifols makes up about 2.2% of Brandes Investment Partners LP’s holdings, making the stock its 5th biggest holding. Brandes Investment Partners LP owned approximately 4.50% of Grifols worth $289,422,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Grifols by 31.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,488,294 shares of the biotechnology company’s stock valued at $24,783,000 after purchasing an additional 600,118 shares in the last quarter. Integrated Quantitative Investments LLC purchased a new stake in shares of Grifols in the 3rd quarter valued at $1,361,000. Envestnet Asset Management Inc. boosted its stake in shares of Grifols by 80.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 515,853 shares of the biotechnology company’s stock valued at $5,138,000 after purchasing an additional 229,661 shares in the last quarter. Diversify Wealth Management LLC purchased a new stake in shares of Grifols in the 3rd quarter valued at $1,156,000. Finally, Hennion & Walsh Asset Management Inc. boosted its stake in shares of Grifols by 31.1% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 478,769 shares of the biotechnology company’s stock valued at $4,476,000 after purchasing an additional 113,539 shares in the last quarter.

Wall Street Analyst Weigh In

GRFS has been the subject of a number of recent analyst reports. Weiss Ratings upgraded shares of Grifols from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Zacks Research lowered shares of Grifols from a “hold” rating to a “strong sell” rating in a report on Friday, May 8th. Finally, Wall Street Zen lowered shares of Grifols from a “buy” rating to a “hold” rating in a report on Monday, May 18th. Three analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce” and an average price target of $10.00.

Grifols Stock Up 0.1%

Shares of NASDAQ GRFS opened at $7.34 on Wednesday. The company has a current ratio of 2.47, a quick ratio of 0.85 and a debt-to-equity ratio of 1.16. Grifols, S.A. has a 12 month low of $7.32 and a 12 month high of $11.14. The firm has a market capitalization of $5.00 billion, a PE ratio of 38.63, a price-to-earnings-growth ratio of 0.28 and a beta of 0.65. The firm has a fifty day simple moving average of $8.04 and a two-hundred day simple moving average of $8.58.

Grifols (NASDAQ:GRFS) last issued its quarterly earnings data on Saturday, February 14th. The biotechnology company reported $0.38 EPS for the quarter. Grifols had a net margin of 5.54% and a return on equity of 6.21%. The business had revenue of $2.32 billion during the quarter. Equities analysts expect that Grifols, S.A. will post 1.06 earnings per share for the current year.

Grifols Company Profile

Grifols, Inc (NASDAQ: GRFS) is a global healthcare company specializing in the development, manufacture and marketing of plasma-derived medicines, diagnostic systems and hospital supplies. With a core focus on immunotherapy and transfusion medicine, the company harnesses human plasma proteins to create therapies that treat a wide range of bleeding disorders, immunodeficiencies and neurological conditions. Grifols also supplies reagents and diagnostic instruments for transfusion centers and clinical laboratories, alongside intravenous solutions and medical devices for hospital use.

The company operates three main business units.